About GLP1 Alpha
Summary: GLP1 Alpha is an independent reference site for GLP-1 receptor agonists. We translate clinical evidence, FDA labels, and trial data into plain language, and we tell readers when something is genuinely uncertain.
This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.
What this site is for
GLP1 Alpha exists because most GLP-1 information online sits in one of two extremes. Manufacturer pages are precise but limited to what their drug does. Lifestyle blogs are accessible but light on the science. We aim for the middle: thorough enough that a careful reader, an early-career clinician, or a curious patient can rely on it, written plainly enough that you do not need a medical degree to follow.
Every article on the site is anchored to primary sources: the FDA prescribing information, the published trial papers in journals like the New England Journal of Medicine and JAMA, and the safety updates from FDA MedWatch. When we cite a number, you can click through to the paper.
Editorial standards
The articles here follow a consistent set of rules:
- Every clinical claim is tied to a primary source. We cite trial papers, FDA labels, and peer-reviewed reviews. Wikipedia, news summaries, and other secondary sources are used for context, not for medical facts.
- Numbers come from the source documents. If we say semaglutide produced a 14.9 percent average body weight reduction, that figure traces to the STEP-1 trial paper. If we cannot find the source, we leave the claim out.
- We name what is uncertain. Many GLP-1 questions have no clean answer yet, including long-term safety beyond five years, the durability of weight loss after stopping, and the comparative cardiovascular benefit between semaglutide and tirzepatide. We say so.
- We update pages when material facts change. The FDA shortage list, new label warnings, and major trial readouts trigger reviews. Each page carries a footer date so you can see how recent the content is.
- We avoid hype language. No game-changers, no miracle drugs, no breakthroughs. The science is interesting on its own.
How we handle commercial relationships
GLP1 Alpha may earn a commission when readers click through to telehealth partners and start a service. Those relationships are listed on the disclaimer page. They do not influence which medications we cover, how we describe outcomes, or which warnings we surface. Adverse effects, contraindications, and limitations are written the same way whether or not we have a commercial partner in the category.
You will see promotional callouts and a sticky banner across the site. Those are clearly marked. Editorial content sits in the main article body and is held to the standards above.
Who writes the content
The site is maintained by an editorial team that combines health-writing experience with primary-source review. Articles are drafted from clinical trial papers, regulatory documents, and recognized clinical references. Where appropriate, we link to the underlying study so you can verify a number directly.
We are not a medical practice. We do not have a clinician-patient relationship with readers, and we do not provide individualized medical advice.
Corrections
If you spot an error, an outdated statistic, a broken link, or a missing source, please email us. We log corrections, fix the article, and update the footer date.
Contact
The fastest way to reach us is by email. We try to reply within two business days.
General questions
Editorial corrections
Spotted an error, an outdated statistic, or a broken citation? Email corrections@glp1alpha.com with the page URL and the issue. We log the correction, fix the article, and update the footer date.